Viatris reports strong fourth quarter and full-year 2021 financial results; issues 2022 financial guidance; completes comprehensive strategic review; unveils plan to reshape the company for the future; announces combination of its biosimilars portfolio with biocon biologics in exchange for up to $3.335 billion representing an attractive multiple to viatris of 16.5x the company's biosimilars 2022e adjusted ebitda(1), the first in a series of expected initiatives anticipated to unlock up to an add

Pittsburgh, feb. 28, 2022 /prnewswire/ -- biocon biologics transaction consists of pre-tax consideration of up to $3.335 billion, including $2 billion in upfront cash, $1 billion of convertible preferred equity representing a stake of at least 12.9% in biocon biologics (on a fully diluted basis), and up to $335 million of additional payments. rajiv malik, viatris president, to represent viatris on biocon biologics board.
VTRS Ratings Summary
VTRS Quant Ranking